Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019

Hyperinflammation is associated with increased mortality in coronavirus disease 2019 (COVID-19). In this retrospective, uncontrolled patient cohort with moderate -severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for th...

Descripción completa

Detalles Bibliográficos
Autores principales: Titanji, Boghuma K, Farley, Monica M, Mehta, Ashish, Connor-Schuler, Randi, Moanna, Abeer, Cribbs, Sushma K, O’Shea, Jesse, DeSilva, Kathryn, Chan, Bonnie, Edwards, Alex, Gavegnano, Christina, Schinazi, Raymond F, Marconi, Vincent C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337637/
https://www.ncbi.nlm.nih.gov/pubmed/32597466
http://dx.doi.org/10.1093/cid/ciaa879

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337637/
https://www.ncbi.nlm.nih.gov/pubmed/32597466
http://dx.doi.org/10.1093/cid/ciaa879

Ejemplares similares